{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vanni S"],"funding":["Ministero della Salute","Italian Ministry of Health"],"pagination":["6926"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10138892"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(8)"],"pubmed_abstract":["Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of the extremities. While MFS is rarely metastasizing, it shows an extremely high rate of multiple frequent local recurrences (50-60% of cases). On the other hand, UPS is an aggressive sarcoma prone to distant recurrence, which is correlated to a poor prognosis. Differential diagnosis is challenging due to their heterogeneous morphology, with UPS remaining a diagnosis of exclusion for sarcomas with unknown differentiation lineage. Moreover, both lesions suffer from the unavailability of diagnostic and prognostic biomarkers. In this context, a genomic approach combined with pharmacological profil"],"journal":["International journal of molecular sciences"],"pubmed_title":["Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need."],"pmcid":["PMC10138892"],"funding_grant_id":["L3P1032"],"pubmed_authors":["Guerrieri AN","Fausti V","Cocchi C","Serra M","Mercatali L","De Vita A","Liverani C","Pieri F","Vanni S","Gurrieri L","Casadei R","Miserocchi G","Recine F","Ibrahim T","Calabrese C","Fonzi E","Spadazzi C","Riva N"],"additional_accession":[]},"is_claimable":false,"name":"Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.","description":"Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one of the most common adult soft tissue sarcoma (STS) of the extremities. While MFS is rarely metastasizing, it shows an extremely high rate of multiple frequent local recurrences (50-60% of cases). On the other hand, UPS is an aggressive sarcoma prone to distant recurrence, which is correlated to a poor prognosis. Differential diagnosis is challenging due to their heterogeneous morphology, with UPS remaining a diagnosis of exclusion for sarcomas with unknown differentiation lineage. Moreover, both lesions suffer from the unavailability of diagnostic and prognostic biomarkers. In this context, a genomic approach combined with pharmacological profil","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-04-07T20:57:59.618Z","creation":"2024-11-20T19:59:43.755Z"},"accession":"S-EPMC10138892","cross_references":{"pubmed":["37108089"],"doi":["10.3390/ijms24086926"]}}